3D Bioprinting Market Size To Touch USD 8.3 Billion By 2030

---

Table of Content

The global 3D bioprinting market size was exhibited USD 2.13 billion in 2022 and is expected to touch around USD 8.3 billion by 2030, growing at a CAGR of 18.51% from 2022 to 2030.

Due to the aging majority's chronic illness prevalence and the lack of organ donations, this market is growing. Throughout the projected timeframe, rising R&D expenditures, technical advancements, and a rise in the number of physical illnesses are also expected to positively affect that industry. In response to the COVID-19 issue, the 3d printer industry has committed to assisting in the manufacturing of crucial medical supplies for institutions coping with this epidemic. 

A use for 3D printers in medicine is 3D bioprinting. By stacking living tissue, this method allows for the 3D printing of human organs and tissues. The three main steps that make it up this 3d printing technology method are increasing in recent times, pre as well as post-bioprinting. 

The finished structure created by 3D bioprinting maintains cell viability and functioning, making it appropriate for research & innovation (R&D) in a range of medical specialties. Creating tissue & organ structures via 3D bioprinting is mostly used for drug and scaffolding development and research as well as the creation of implantable devices.

Report Highlights:

• ADAM introduced 3D biomaterials of biological bone formations in April 2019. It makes use of novel materials combined with inventive methods for 3D printing. The first is a ceramics bioglass, while the other is a biomaterial. To ensure their global hegemony in the 3D bioprinting industry, the market participants have employed new product releases, design and development, merchandise approvals, collaborations, agreements, and partnerships as their main business advancement tactics. 
• The rise in the elderly population increased focus on R&d spending, and technical advances for producing customized products are only a few of the factors driving the anticipated considerable expansion of the worldwide 3D bioprinting market throughout the forecast period. 
• Increased use of 3d printers in aesthetic procedures and advancements in 3D bioprinting is also anticipated to support the development of a 3D bioprinting industry throughout the projected timeframe. Additionally, there is a significant need for kidney transplants between patients and medical professionals, and the newly developed bioprinting technology has a promising future in bridging this divide. 
• Even though these reasons encourage market expansion, a significant barrier to that expansion may be the lack of qualified personnel to operate the highly sophisticated 3D bioprinters. In contrast, it is anticipated that increased research into stem cells and increased public knowledge of 3D bioprinting would present lucrative prospects for market participants in this sector.

3D Bioprinting Market Report Scope

Regional Snapshots:  

The Asia-Pacific 3D printing technology market is expected to generate an overall revenue of 23.7% in 2021, and the region is expected to hold the top spot throughout the forecast period. China and Japan provided the most to the region's overall revenue because of the rising COVID-19 cases and rising government R&D spending.

Around 87,706 COVID-19 cases have been reported in China as of January 13th, 2021, according to the world meter Survey 2021. Furthermore, it is anticipated that COVID-19's increased mortality rate and the shortage of organ donors will significantly boost the 3D bioprinting sector in this region. 

North America held the largest market share globally in 2021. Due to large public and private investments in the development of cutting-edge 3D bioprinting technology, its quick adoption, and the presence of key market players in the region, North America owns a sizeable percentage of the industry.

Market Dynamics

Drivers

Many pharmaceutical companies are quickly adopting 3D bioprinting products and technology in the search for and development of new medicines. The drug business can test medications more affordably and safely thanks to 3D bioprinting it could compared to the traditional drug test procedure. 

The 3D bioprinting technique enables pharmaceutical companies to test a medication in a matter of hours, cutting the three to six years it traditionally takes to develop a new therapy. Using 3D bioprinted tissues, R&D teams can test potential treatments early on and during preclinical investigations. Benefits of 3D bioprinting include fewer animal tests, higher productivity, and quicker medication development. 

People's knowledge of 3D printing has expanded as its use has increased, especially in the cosmetics industry. Additionally, since March 2013, the European Commission had outlawed animal testing for cosmetics. In response, several businesses in the healthcare and cosmetics industries have used 3D bioprinting to develop cutting-edge 3D tissue models and methods for drug screening.

Restraints: 

A growing area in the healthcare sector is 3D bioprinting. The need for qualified individuals in the industry is increasing as a result of ongoing technological improvements. Process control must be ongoing for 3D bioprinting technologies to be used effectively. 

Due to uncontrollable process variables (such as the variance across batch and equipment) and materials variations, the uniformity of the operation differs across multiple platforms. To effectively use and comprehend the 3D bioprinter, one must possess the knowledge and abilities of a trained specialist in these procedures and technologies. The ability to design spatial objects is the most crucial component of the 3d printer's service.

Opportunities: 

3D printing is playing an increasingly important role in the medical field since it has the potential to manufacture complex solid organs like kidneys, the heart, and lungs for transplant. 3D-printed parts are less likely to pose dangers than the conventional replacement of failing or wounded organs, which carries the risk of the human host rejecting them because they use blood-derived cells. 

3D bioprinting holds great potential for the future of medicine since it may be used to generate new organs during organ transplants and heal broken bones. Additionally, it enables the printing of prosthetic limbs that can be used to replace individuals' lost legs.

Challenges: 

The accuracy of the additive manufacturing process differs between machines as a result of unpredictable processing parameters and various materials. A few monitoring methods are available to help producers correct these alterations and meet their particular requirements. 

The lack of systems integration knowledge has made it difficult to develop complex and accurate mathematical models utilizing additive manufacturing. These limitations on preproduction, planning, and control systems typically result in expensive errors and unsuccessful manufacturing.

Recent Developments:

• BICO Company AB (USA) debuted The BIO CELLX in March 2022. This ground-breaking technology automates 3D cell cultivation processes by using prevalidated techniques.
• In June 2021, 3d Printers, Inc. (US) and CollPlant Biomaterials Limited inked a co-development agreement for such a 3D-bioprinted regenerating tissue substrate to be employed in reconstructive surgery procedures in conjunction with an implant (Israel).
• The 2019 release of the CELLINK Epidermis Kit includes CELLINK LIVER Kits. These kits provide information on the phenotypic characteristics of their tissue analogs, which helps researchers create reliable tissue designs for pharmacological and cosmetics research.
• Allevi's Epidermis Bioink Kit, which can grow skin patches, was released in 2019.
• In 2019, Organovo collaborated with Ton Rabelink from the Murdoch Children's Research Facility in Australia and Leiden University in the Netherlands. They want to expand and advance the usage of 3D-bioprinted cell lines for the treatment of advanced renal disease.
• In 2019, Digilab collaborated with Orgenesis, Inc., a US business. They aimed to develop functional cell manufacturing methods and procedures to automate the synthesis of three-dimensional living cell membranes and tissue.
• EnvisionTEC and Covestro announced their partnership on material printer choices in September 2021 to lower entry barriers for companies desiring to adopt 3D printing for producing molds for small runs or components with specific properties more quickly and profitably.

Major Key Players:

• 3D Bioprinting Solutions
• Advanced Solutions Life Sciences, LLC
• Allevi Inc.
• Aspect Biosystems Ltd.
• Bico group ab
• Bio3D Technologies Pte. Ltd.
• Cellink Global
• Collplant Biotechnologies Ltd.
• Cyfuse Biomedical K.K.
• Electro Optical Systems
• EnvisionTEC, Inc.
• Foldink Life Science Technologies
• Formlabs, Inc.
• GE Healthcare
• Inventia Life Science PTY LTD
• Optomec Inc.
• Organovo Holdings Inc
• Pandorum Technologies pvt. ltd.
• Poietis
• Precise Bio
• Regenovo Biotechnology Co. Ltd.
• Renishaw plc.
• Revotek co., ltd.
• Rokit Healthcare, inc.
• Stratasys Ltd.Vivax Bio, LLC

Market Segmentation:

By Component

• 3D Bioprinters
• Bioinks  

By Technology 

• Magnetic Levitation
• Inkjet-based
• Syringe-based
• Laser-based
• Others

By Application

• Research Applications
• Clinical Applications

By End User

• Research Organizations and Academic Institutes
• Biopharmaceutical companies
• Hospitals

Buy this Research Report@ https://www.precedenceresearch.com/checkout/2107

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com| +1 9197 992 333